论文部分内容阅读
目的：探讨 Ｃ Ｅ Ａ、 Ｃ Ａ５０ 联合测定在胃肠道恶性肿瘤诊断、疗效观察，术后监测的价值。方法： 分别测定正常人、良性疾病患者和４７０ 例胃肠道恶性肿瘤患者以及６３ 例胃肠道恶性肿瘤术后患者的血清 Ｃ Ｅ Ａ、 Ｃ Ａ５０ 水平。结果：胃癌患者 Ｃ Ｅ Ａ 阳性率为６０ ．００ ％ ， Ｃ Ａ５０ 阳性率为６８ ．００ ％ ，联合测定阳性率为８３ ．３３ ％ ；大肠癌患者的 Ｃ Ｅ Ａ 阳性率为７０ ．３１ ％ ， Ｃ Ａ５０ 阳性率为７５ ．００ ％ ，联合测定阳性率为８８ ．１２ ％ 。随访６３ 例术后患者中，有４１ 例患者血清可见 Ｃ Ｅ Ａ 或 Ｃ Ａ５０ 升高，在血清学变化的３ ～１２ 月内被临床证实转移或复发。结论：联合测定 Ｃ Ｅ Ａ、 Ｃ Ａ５０ 不仅可提高胃肠道恶性肿瘤的阳性诊断率，还可进行疗效观察及术后监测。
Objective: To investigate the value of combined detection of C E A and C A 50 in the diagnosis, efficacy and postoperative monitoring of gastrointestinal cancer. Methods: Serum C E A and C A 50 levels were measured in normal and benign patients, 470 patients with gastrointestinal cancer, and 63 patients with gastrointestinal cancer. Results: The positive rate of C E A in gastric cancer patients was 60. 00 % , C A 50 positive rate was 68. At 00 %, the combined positive rate was 83. 33%; The positive rate of C E A in patients with colorectal cancer was 70. 31%, C A 50 positive rate was 75. At 00 %, the combined positive rate was 88. 12%. Of the 63 patients who were followed up, 41 patients showed elevated C E A or C A 50 sera and were clinically confirmed to have metastasized or relapsed within 3 to 12 months of serologic change. Conclusion: Combined determination of C E A and C A 50 can not only improve the positive diagnosis rate of gastrointestinal malignant tumors, but also can observe the effect and postoperative monitoring.